Barely Significant
← all excerpts

Novel Approaches to Arteriovenous Access Creation, Maturation, Suitability, and Durability for Dialysis.

Kidney Int Rep · 2020 · PMC7270716 · PMID 32518859

Europe PMCDOI
1
hedged sentence
0.3280
closest p · 6.6× alpha
0.3280
boldest claim

The sentences

did not achieve significanceP = 0.328not close (p > 0.1)
In April 2019, the sponsor company, Proteon Therapeutics (Waltham, MA), reported that the study did not achieve significance; at 12 months, 69.7% of vonapanitase-treated AVF were in use, compared with 65.1% in the control group ( P = 0.328).

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.